Hammersmith Hospital

Running trials

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· Source

• Recruiting

  A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing Haemodialysis

  NCT07422532· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Source

• Recruiting

  Prospective Evaluation of AI-ECG for SHD Detection

  NCT07057466· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· Source

• Recruiting

  A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

  NCT06786234· Phase 2· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  NCT06925750· Phase 2· Source

• Active, not recruiting

  Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

  NCT06814145· Phase 2· Source

• Recruiting

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Phase 2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Source

• Recruiting

  A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  NCT06500884· Phase 2· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

  NCT06226571· Phase 1· Source

• Recruiting

  Ablation of Focal Activation in Atrial Fibrillation

  NCT06402617· Source

• Active, not recruiting

  Differentiation of Benign From Malignant Thyroid Nodules Using Diffuse Reflectance Spectroscopy

  NCT07124065· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Source

• Active, not recruiting

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· Phase 3· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Recruiting

  Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

  NCT06052475· Source

• Recruiting

  Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

  NCT05967143· Source

• Active, not recruiting

  Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

  NCT05755711· Source

• Recruiting

  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  NCT05786924· Phase 1/2· Source

• Active, not recruiting

  Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

  NCT05612035· Phase 2· Source

• Recruiting

  The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF

  NCT05539040· Source

• Active, not recruiting

  A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

  NCT05578976· Phase 3· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

  NCT05768386· Phase 4· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Source

• Active, not recruiting

  Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

  NCT05456685· Phase 2· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Source

• Recruiting

  A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT05519085· Phase 3· Source

• Recruiting

  Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

  NCT05185739· Phase 2· Source

• Recruiting

  Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

  NCT05254171· Phase 2/3· Source

• Recruiting

  MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

  NCT05487612· Source

• Recruiting

  Lutathera and ASTX727 in Neuroendocrine Tumours

  NCT05178693· Phase 1· Source

• Recruiting

  OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

  NCT04493632· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Source

• Recruiting

  A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

  NCT05037760· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

  NCT04712097· Phase 3· Source

• Recruiting

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma5 recruiting
• Liver and biliary tract cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pancreatic cancer3 recruiting
• Type 2 diabetes3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Colorectal cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Obesity2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sickle cell disease2 recruiting
• Acute myeloid leukemia1 recruiting
• Asthma1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Haemophilia1 recruiting
• Hodgkin lymphoma1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Phase 1· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

  NCT05844566· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Source

• Completed

  A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

  NCT04987489· Phase 2· Source

• Completed

  A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

  NCT04912869· Phase 1· Source

• Completed

  A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

  NCT05075824· Phase 2· Source

• Completed

  A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

  NCT05091346· Phase 1/2· Source

• Terminated

  The Long-term Safety and Effect of Renal Denervation

  NCT05818813· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  Long Term Extension Trial of Setmelanotide

  NCT03651765· Phase 2/3· Source

• Completed

  Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

  NCT03117933· Phase 2· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· Source

Trial sites

• Hammersmith Hospital1 trial
• Department of Cardiothoracic Surgery, Hammersmith Hospital1 trial
• Hammersmith Hospital63 trials
• Hammersmith Hospital, Clinical Research Facility, Centre for Translational and Experimental Medicine1 trial
• Hammersmith Hospital-Department of Cardiology (Site 0900)1 trial
• Hammersmith Hospital-Department of Cardiology (Site 2401)1 trial
• Hammersmith Hospital - Haematology Dept1 trial
• Hammersmith Hospital /ID# 1714461 trial
• Hammersmith Hospital /ID# 2159781 trial
• Hammersmith Hospital /ID# 2422151 trial
• Hammersmith Hospital /ID# 2611241 trial
• Hammersmith Hospital /ID# 2689451 trial
• Hammersmith Hospital /ID# 2746151 trial
• Hammersmith Hospital London3 trials
• Hammersmith Hospital (Site 0533)1 trial
• Hammersmith Hospital (Site 0915)1 trial
• Hammersmith Hospital (Site 1203)1 trial
• Hammersmith Hospital (Site 1801)2 trials
• Hammersmith Hospital (Site 4001)1 trial
• Hammersmith Hospital (Site 4010)1 trial
• Imperial College London - Hammersmith Hospital3 trials
• Imperial College London, Hammersmith Hospital, Surgery&Cancer1 trial
• NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Pulmonary arterial hypertension20 works · 11 trials
• Chronic myeloid leukaemia5 works · 2 trials